Comment: Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective

Khanderia U , Pop-Busui R , Eagle KA . Thiazolidinediones in type 2 diabetes: a cardiology perspective. Ann Pharmacother 2008;42:1466–74. Epub 12 Aug 2008. DOI 10.1345/aph.1K666

Dormandy JA , Charbonnel B , Eckland DJ . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. Lancet 2005;366:1279–89.

Richter B , Bandeira-Echtler E , Bergerhoff K , Clar C , Ebrahim SH . Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No. CD006060. DOI 10.1002/14651858.CD006060.pub2

Lincoff AM , Wolski K , Nicholls SJ . Pioglitazone and risk of cardiovascular events inpatients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180–8.

Richter B , Bandeira-Echtler E , Bergerhoff K , Clar C , Ebrahim SH . Rosiglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No. CD006063. DOI 10.1002/14651858.CD006063.pub2